Argus raised Integra Lifesciences' price objective from $55 to $61 in a research report, according to a Mideast Times report.
Here are four things to know:
• Argus currently has a "buy" rating on the stock.
• The company has a one-year low of $42.50 and a one-year high of $58.25.
• The stock's 50-day moving average is $55.6 and its 200-day moving average is $50.80.
• The company has a market cap of $1.849 billion.
Separately, Zacks analysts reiterated a neutral rating and set a $54 price target on Integra shares in a research note on Dec. 18, according to the report.
More articles on devices:
7 key trends in joint replacement customization
Amedica files FDA application for spinal implant spacers with porous silicon nitride center — 6 things to know
Revenue up, $147k net loss — 10 key points on RTI Surgical's 2014 financial report